• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

News

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News

News · January 20, 2011

James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals

Additional Management Team Announcement with Promotion of Robert Silverman January 19, 2011, Lexington, MA -- Concert Pharmaceuticals, Inc. announced today the appointment of James E. Shipley, M.D., …

News · January 17, 2011

Precision Therapeutics Announces New Study on Multi-Gene Predictors at 2010 San Antonio Breast Cancer Symposium

PITTSBURGH, Jan. 17, 2011 /PRNewswire/ -- In a new study in which Precision Therapeutics' Multi-Gene Predictors (MGPs) were independently validated by investigators at US Oncology and MD Anderson, …

News · January 13, 2011

New Patents Continue to issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property

January 13, 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity …

News · January 7, 2011

Anchor Therapeutics Achieves Milestone in GPCR Collaboration

-- Significant Progress Over First Four Months of Joint Research -- Cambridge, MA - January 7, 2011 - Anchor Therapeutics today announced that it has successfully completed the first stage of its …

News · January 5, 2011

EUSA Pharma Announces Priority Review Status for ERWINAZE® BLA

Langhorne, PA and Oxford, UK – 5 January 2011 EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its …

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 49
  • Go to page 50
  • Go to page 51

Primary Sidebar

Secondary Sidebar

Additional News

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

March 17, 2023

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

February 23, 2023

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

February 21, 2023

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

February 1, 2023

Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement

August 1, 2022

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact